

SWOG ASCO 2023 ANNUAL MEETING ABSTRACTS

SWOG-LED:

S0226 Cobain E, Barlow W, Paoletti C, Bergqvist M, Williams A, Ritzen H, Mehta R, Gralow J, Hortobagyi G, Albain K, Puztai L, Sharma P, Godwin A, Thompson A, Hayes D, Rae J. Comparing the Prognostic and Predictive Utility of Serum Thymidine Kinase 1 and CA 15-3 in Patients with Hormone Receptor Positive Metastatic Breast Cancer Starting First-Line Endocrine Therapy in SWOG S0226. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session, 2023. <https://meetings.asco.org/abstracts-presentations/222604>

S0777 Brian Durie, Shaji Kumar, Eric Ammann, Alex Fu, Shuchita Kaila, Annette Lam, Saad Usmani, Thierry Facon. Adjusted indirect treatment comparison of progression-free survival (PFS) associated with DRd and VRd based on MAIA and SWOG S0777 individual patient-level data. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session, 2023. <https://meetings.asco.org/abstracts-presentations/226705>

S0931 Shuchi Gulati, Catherine Tangen, Christopher Ryan, Ulka Vaishampayan, Brian Shuch, Pedro Barata, Deepak Pruthi, Cristiane Bergerot, Abhishek Tripathi, Ian Thompson, Primo Lara, Sumanta Pal. Adjuvant everolimus in patients (Pts) with localized non-clear cell renal cell carcinoma (RCC): Subgroup analysis from the Everest trial (SWOG S0931). ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session, 2023. <https://meetings.asco.org/abstracts-presentations/218132>

S1011 Lerner SP, Tangen C, Svatek R, Daneshmand S, Pohar K, Skinner E, Schuckman A, Sagalowsky A, Smith N, Kamat A, Kassouf W, Plets M, Bangs R, Koppie T, Alva A, La Rosa F, Pal S, Kibel A, Canter D, Thompson I. SWOG S1011 - A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral, 2023. <https://meetings.asco.org/abstracts-presentations/218067>

S1216 Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski J, Ingles S, Triche T, MacVicar G, Vaena D, Crispino A, McConkey D, Lara P, Hussain M, Quinn D, Dorff T, Thompson I, Agarwal N. Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus

orteronel (cyp17 inhibitor) or bicalutamide. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session, 2023.

<https://meetings.asco.org/abstracts-presentations/218390>

S1216 Lara P, Mayerson E, Gertz E, Tangen C, Goldkorn A, van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn D, LeBlanc M, Thompson I, Agarwal N. Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): results from the Phase III SWOG S1216 trial of androgen deprivation +/- orteronel. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session, 2023. <https://meetings.asco.org/abstracts-presentations/222717>

S1216 Parikh M, Tangen C, Hussain M, Gupta S, Jo Y, Harzstark A, Paller C, George S, Zibelman M, Cheng H, Maughan B, Zhang J, Pachynski R, Bryce A, Lin D, Quinn D, Thompson I, Dorff T, Lara P, Agarwal N. Prostate-Specific Antigen at 3 & 7 months (PSA-3mo, PSA-7mo) Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Treated with Androgen Deprivation With or Without Orteronel (SWOG S1216). ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session, 2023. <https://meetings.asco.org/abstracts-presentations/222729>

S1216 Sayegh N, Swami U, Jo Y, Tangen C, Gebrael G, Haaland B, Gupta S, Plets M, Hussain M, Quinn D, Lara P, Thompson IM, Agarwal N. Outcomes of African American (AA) versus Caucasian (CA) men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without orteronel (O): Analysis of patient-level data from the SWOG-1216 phase 3 trial. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session, 2023. <https://meetings.asco.org/abstracts-presentations/221808>

S1500 Tripathi A, Tangen C, Li X, Tretiokova M, Humphrey P, Adeniran A, Barata P, Gulati S, Bergerot C, Pruthi D, Thompson I, Lara P, Pal S, Shuch B. Pathologic Concordance Rate and Outcomes by Histologic Subtype in Advanced Papillary Renal Cell (pRCC) Carcinoma: an Analysis from the SWOG S1500 (PAPMET) Trial. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session, 2023. <https://meetings.asco.org/abstracts-presentations/219970>

S1505 Patel SH, Colby S, Sohal D, Guthrie K, Kachnic L, Chiorean E, Lowy A, Rocha F, Philip P, Ahmad S. Chemotherapy Dose Density is Prognostic for Patients with Resectable Pancreas Cancer: A Secondary Analysis of SWOG S1505. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session, 2023. <https://meetings.asco.org/abstracts-presentations/220985>

S1609 Chae Y, Othus M, Patel S, Edwards R, Scalici J, Il-Young Chung L, McLeod C, Chen H, Sharon E, Streicher H, Ryan C, Blanke C, Kurzrock R. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Vulvar Cancers. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session, 2023. <https://meetings.asco.org/abstracts-presentations/221791>

S1609 Chae YK, Othus M, Patel S, Powers B, Hsueh C-T, Govindarajan R, Bucur S, Il-Young Chung L, McLeod C, Chen H, Sharon E, Streicher H, Ryan C, Blanke C, Kurzrock R. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Desmoid Tumors (Cohort 27). ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session, 2023. <https://meetings.asco.org/abstracts-presentations/220010>

S1609 Othus M, Patel S, Chae Y, Dietrich E, Streicher H, Sharon E, Kurzrock R. Change in RECIST Tumor Size Correlates Linearly with Survival in Patients Treated with Checkpoint Inhibitor Therapy (SWOG S1609). ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral, 2023. <https://meetings.asco.org/abstracts-presentations/222691>

S1609 Patel S, Guadarrama E, Chae Y, Liao C-Y, Kasi A, Tarabay G, George T, Chung L, Lopez G, McLeod C, Othus M, Chen H, Sharon E, Streicher H, Ryan C, Blanke C, Kurzrock R. A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with refractory gallbladder cancer (cohort 48). ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), publication only, 2023. <https://meetings.asco.org/abstracts-presentations/222211>

S1714 Trivedi M, Unger J, Hershman D, Darke A, Hertz D, Brannagan T, Smith S, Schneider B, Irvin W, Hathaway A, Vander Woude A, Gudena V, Henry NL, Fisch M. Chemotherapy Induced Peripheral Neuropathy (CIPN) due to Paclitaxel versus Docetaxel in Patients with Early-Stage Breast Cancer Receiving Taxane Therapy: SWOG S1714 (NCT# 03939481). ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), accepted oral, 2023. <https://meetings.asco.org/abstracts-presentations/223187>

S1802 Bsteh D, Buckley J, Ostrow D, Parmentier J, Maganti S, Mitchell S, Sadis S, Smith J, Ni J, Peng X, Plets M, Tangen C, Aparicio A, Chapin B, Quinn D, McConkey D, Dorff T, Thompson I, Triche T, Goldkorn A. HERCULES: A prostate cancer (PC) sequencing panel for parallel analysis of

circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) (SWOG S1802). ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session, 2023. <https://meetings.asco.org/abstracts-presentations/222758>

S1826 Herrera A, Li H, Costellino S, Rutherford S, Evens A, Davidson K, Punnett A, Hodgson D, Parsons S, Ahmed S, Casulo C, Bartlett N, Song J, Little R, LeBlanc M, Kahl B, Leonard J, Kelly K, Smith S, Friedberg J. Nivolumab-AVD Improves Progression-Free Survival (PFS) Compared to Brentuximab Vedotin-AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma (HL), Results of SWOG S1826. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral plenary session, 2023. <https://meetings.asco.org/abstracts-presentations/219808>

S1900E Padda S, Redman M, Gerber D, Stinchcombe T, Waqar S, Leal T, Minichiello K, Reckamp K, Herbst R, Borghaei H, Brahmer J, Gray J, Kelly K, Ramalingam S, Neal J. ECOG-ACRIN LUNG-MAP S1900E Substudy (NCT04625647): A Phase II Study of Sotorasib in Participants (Pts) With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous (Non-sq) Non-Small Cell Lung Cancer (NSCLC). ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), TIP, poster session, 2023. <https://meetings.asco.org/abstracts-presentations/226043>

S1929 Abdel Karim N, Miao J, Reckamp K, Gay C, Byers L, Zhao Y, Redman M, Carrizosa D, Wang W, Petty W, Mehta K, Faller B, Agamah E, Kasbari S, Malisetti Rajini, Kumar A, Schallenkamp J, Alluri K, Gray J, Kelly K. SWOG S1929: Phase II Randomized Study of Maintenance Atezolizumab (A) Versus Atezolizumab + Talazoparib (AT) in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC). ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral, 2023. <https://meetings.asco.org/abstracts-presentations/218832>

S1937 Sadeghi S, Plets M, Lara P, Tangen C, Bangs R, Lerner S, Flaig T, Petrylak D, Thompson I. A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), tips, poster, 2023. <https://meetings.asco.org/abstracts-presentations/225898>

S2000 Eroglu Z, Moon J, Tawbi H, Najjar Y, Kotecha R, Spektor V, Wu M, Sharon E, Wolchok J, Patel S. A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT#

04511013). ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), TIP poster session, 2023. <https://meetings.asco.org/abstracts-presentations/226078>

S2001 Chung V, Guthrie K, Pishvaian M, Reiss K, Lowy A, Sohal D, Colby S, Sharon E, Allegra C, O'Reilly E, Chiorean E, Philip P. Randomized Phase II Trial of Olaparib + Pembrolizumab vs Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 (gBRCA1/2+) Mutations: SWOG S2001 NCT04548752. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), TIP poster session, 2023. <https://meetings.asco.org/abstracts-presentations/225877>

LUNGMAP Mack P, Redman M, Kozono D, Callis S, Tukachinsky H, Tolba K, Neal J, Waqar S, Dragnev K, Aggarwal C, Hirsch F, Patel J, Herbst R, Chiang A, Reckamp K, Kelly K, Borghaei H, Gray J, Gandara D. The effect of ctDNA Tumor Fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session, 2023. <https://meetings.asco.org/abstracts-presentations/218935>

MULTIPLE Hershman D, Vaidya R, Till C, Barlow W, LeBlanc M, Ramsey S, Unger J. Association of Baseline Measures of Socioeconomic Deprivation and Healthcare Utilization in Patients Enrolled in SWOG Cancer Clinical Trials. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session, 2023. <https://meetings.asco.org/abstracts-presentations/220532>

MULTIPLE* Morin Coulombe A, Ozgun G, Johnson R, Lewis M, Adra N, Eggener S, Roth B, Ryan C, Porter C, Millard F, Jang T, Hamilton R, Einhorn L, Kollmannsberger C, Arnold K, Blanke C, Daneshmand S, Nichols C, Nappi L, Harzstark A. SWOG S1823/CCTG GCC1 - Translational Observational Investigational Study of the Liquid Biomarker microRNA 371a-3p in Newly Diagnosed Germ Cell Tumours - Real-World Trial Design, Rapid Accrual, and Robust Secondary Use of Data Opportunities. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), TIP poster session, 2023. [*S1823, OTHER] <https://meetings.asco.org/abstracts-presentations/225919>

MULTIPLE Preasant C, Vaidya R, Till C, Ashing K, Warren G, Hershman D, Sun V, Subbiah S, Salgia R, Massarelli E, Mortimer J, Fakhri M, Pal S, Amini A, Erhunmwuse L, Phillips T, Rosen S, Unger J. The Association of Sociodemographic Variables with Smoking Prevalence in Patients

Enrolled on Clinical Trials. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), publication only, 2023. <https://meetings.asco.org/abstracts-presentations/219424>

MULTIPLE Joseph Unger, Caroline Schenkel, Hillary Stires, Laura Levit, Mark Stewart, Brittany McKelvey, Beverly Canin, Emily Dressler, Keith Flaherty, Peter Fredette, Lee Jones, Margaret McCann, Therica Miller, Adedayo Onitilo, Frances Palmieri, Timil Patel, Rocio Paul, Gary Smith, Suanna Bruinooge, Ajjai Alva. Impact of COVID-19 pandemic mitigation strategies on industry and NCI cancer treatment trials. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), accepted, poster session, 2023. <https://meetings.asco.org/abstracts-presentations/219437>

MULTIPLE Manuel Espinoza Gutarra, Colmar Figueroa-Moseley, Lucy Gansauer, Gayathri Nagaraj, Jessica McDermott, Rick Bangs, Allison Caban-Holt, Patricia Robinson. Leadership knowledge and beliefs regarding diversity, equity, and inclusion at SWOG Cancer Research Network. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), publication only, 2023. <https://meetings.asco.org/abstracts-presentations/224880>

MULTIPLE Colmar Figueroa-Moseley, Lucy Gansauer, Jessica McDermott, Manuel Espinoza Gutarra, Gayathri Nagaraj, Patricia Robinson, Rick Bangs, Allison Caban-Holt. Diversity, equity, and inclusion (DEI) champions: Lessons learned and implications for future programming to support cancer clinical trials. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), publication only, 2023. <https://meetings.asco.org/abstracts-presentations/223882>

THF SEED Okado I, Liu M, Elhadj C, Wilkens L, Holcombe R. Rural cancer care delivery during the COVID-19 pandemic for patients with early-stage cancer. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), publication only, 2023. <https://meetings.asco.org/abstracts-presentations/223950>

OTHER GROUP-LED:

A021804 Del Rivero J, Perez K, Geyer S, Khalil M, Vijendran A, Kordaris-Corkill A, Shegrill A, Soares H, Lopez C, Nixon A, Dueck A, Meyerhardt J, O'Reilly E. A021804: A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide versus Temozolomide and Olaparib for Advanced

Pheochromocytoma and Paraganglioma. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), accepted, poster session, 2023.

<https://meetings.asco.org/abstracts-presentations/225867>

A021806 Chawla A, Shi Q, Ko A, Beg M, Varghese A, Noel M, Bloomston M, Ahmed F, Frankel W, Dixon J, Carrero X, Shergill A, Crawley J, Akin O, Renouf D, Zogopoulos G, Hubbard J, Meyerhardt J, O'Reilly E, Ferrone C. Alliance A021806: A phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), accepted, poster session, 2023.

<https://meetings.asco.org/abstracts-presentations/225889>

A022004 Yaeger R, Shi Q, Dueck A, Dib E, Kazmi S, Alese O, Krishnamurthi S, Nixon A, Shergill A, O'Reilly E, Meyerhardt J. Randomized Trial of Consolidation Targeted Adjuvant Therapy with Encorafenib and Cetuximab Versus Usual Care for Patients with Stage II/III BRAF V600E Colon Cancer (Alliance A022004). ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), accepted, poster session, 2023.

<https://meetings.asco.org/abstracts-presentations/225855>

A022101 Hitchcock K, Romesser P, Shi Q, Dixon J, Gholami S, White S, Wu C, Goulet C, Jee K, Wright C, Yaeger R, Shergill A, Hong T, George T, O'Reilly E, Meyerhardt J, Miller E. A022101: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer - evaluating radiation, ablation, and surgery (ERASur). ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), accepted, poster session, 2023. <https://meetings.asco.org/abstracts-presentations/225844>

A041702 Woyach J, Yin J, Brown J, Dinner S, Lozanski G, Little R, Miller C, Coutre S, Ding W, Hill B, Perez G, Ruppert A, Wall A, Feldman D, Dib E, Erba H, Stone R, Byrd J. Results of a Phase 3 study of IVO vs IO for Previously Untreated Older Patients with CLL and Impact of COVID-19. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), accepted, oral, 2023. <https://meetings.asco.org/abstracts-presentations/218267>

A091902 Olson J, Allred J, Schuetze S, Davis E, Poklepovic A, Wagner M, Waechter B, Reidel R, Xu-Welliver M, Berg S, George S, Robinson S, Gooe P, D'Angelo S, Schwartz G. A multicenter phase II study of cabozantinib + nivolumab for patients with advanced angiosarcoma previously treated with a taxane (Alliance A091902). ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), accepted, oral, 2023.

<https://meetings.asco.org/abstracts-presentations/218376>

A092001 Mansfield A, Goodrich A, Foster N, Ernani V, Villaruz L, Forde P, Raghav K, Romesser P, Garbacz K, Cao L, Salvatore M, Roden A, Powell S, Shergill A, Munster P, Schwartz G, Grotz T. Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or without Immunotherapy for Peritoneal Mesothelioma (Alliance A092001). ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), accepted, poster session, 2023. <https://meetings.asco.org/abstracts-presentations/226037>

A022104/NRG-GI010 Smith JJ, Dasari A, Shi Q, Garcia-Aguilar J, Sanoff H, George T, Hong T, Yothers G, Philip P, Nelson G, Al Baghdadi T, O'Reilly E, Meyerhardt J, Shergill A, Horvat N, Romesser P, Hall W. A022104/NRG-GI010: A RANDOMIZED PHASE II TRIAL TESTING THE EFFICACY OF TRIPLET VERSUS DOUBLET CHEMOTHERAPY TO ACHIEVE CLINICAL COMPLETE RESPONSE IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER | THE JANUS RECTAL CANCER TRIAL. ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), accepted, poster session, 2023. <https://meetings.asco.org/abstracts-presentations/225852>

N1048 Schrag D, Quian S, Weiser M, Gollub M, Saltz L, Chang G, Auer R, Farma J, George T, Gordon V, Musher B, Goldberg J, Kolevska T, Dueck A, Basch E, Venook A, Goodman K, O'Reilly E, Meyerhardt J, Mamon H. PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by Total Mesorectal Excision (TME) for treatment of locally advanced rectal cancer (LARC). ASCO Annual Meeting (June 2-6, 2023, Chicago, IL) LBA, accepted, oral plenary session, 2023. <https://meetings.asco.org/abstracts-presentations/219804>

MULTIPLE Susan Halabi, Siyuan Guo, Akash Roy, Larysa Rydzewska, Peter Godolphin, Maha Hussain, Catherine Tangen, Ian Thompson, Wanling Xie, Michael Carducci, Matthew Smith, Michael Morris, Gwenaelle Gravis, David Dearnaley, Paul Verhagen, Takayuki Goto, Nicholas James, Mahesh Parmar, Marc Buyse, Christopher Sweeney. The relationship between a priori defined prognostic risk groups and overall survival (OS) in men with metastatic hormone sensitive prostate cancer (mHSPC). ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), accepted, poster session, 2023. <https://meetings.asco.org/abstracts-presentations/222722>

MULTIPLE Susan Halabi, Akash Roy, Siyuan Guo, Larysa Rydzewska, Peter Godolphin, Maha Hussain, Catherine Tangen, Ian Thompson, Wanling Xie, Michael Carducci, Matthew Smith, Michael Morris, Gwenaelle Gravis, David Dearnaley, Paul Verhagen, Takayuki Goto, Jayne Tierney, Nicholas James, Marc Buyse, Christopher Sweeney. Assessing PSA levels as prognostic of overall survival (OS) in men with metastatic

hormone-sensitive prostate cancer (mHSPC). ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), accepted, poster session, 2023.
<https://meetings.asco.org/abstracts-presentations/222713>